Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

Interferon gamma-1b is under clinical development by Amgen and currently in Phase II for Relapsed Acute Myeloid Leukemia.

There are three different types of thyroid dysfunction associated with IFN treatment: (1) autoimmune (often subclinical) hypothyroidism; (2) destructive thyroiditis; and (3) Graves ...

A new study showed that SOCS1 regulation of GM-CSF signaling is dose-dependent. The study, which involved generating a novel ...